DEF 14A: TherapeuticsMD, Inc. Announces Annual Meeting of Stockholders and Proxy Statement

TherapeuticsMD, Inc. will hold its annual meeting of stockholders virtually on December 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of an independent auditor.

Summary

• TherapeuticsMD, Inc. will hold its Annual Meeting of Stockholders on December 5, 2024, at 8:00 a.m. Eastern Time, conducted virtually via live webcast.
• Stockholders of record as of October 17, 2024, are entitled to vote at the meeting.
• The meeting's agenda includes the election of four directors, an advisory vote on executive compensation for the fiscal year ended December 31, 2023, and the ratification of Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent auditor for the fiscal year ending December 31, 2024.
• The company is distributing proxy materials electronically, with instructions on how to access the documents and vote online or request paper copies.
• The Board of Directors recommends voting for the election of the director nominees, the approval of executive compensation, and the ratification of the independent auditor appointment.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The Board's recommendations suggest a positive outlook on the company's direction.

Positives

• The company is using electronic distribution of proxy materials to reduce environmental impact and costs.
• The Board of Directors is actively engaged in risk oversight through its committees.
• The company has a compensation recovery (clawback) policy in place.
• The company has an anti-hedging and anti-pledging policy for its securities.
• The company encourages directors to attend the annual meeting of stockholders.

Negatives

• The company's reports on the company's financial statements as of and for the fiscal years ended December 31, 2022 and 2021 included an explanatory paragraph describing the uncertainty of the company's ability to continue as a going concern.
• The company incurred $868,224 in accounting fees in 2022.

Risks

• The company faces operational, economic, financial, legal, regulatory, and competitive risks.
• The advisory vote on executive compensation is non-binding.
• The company's future performance is subject to various market and economic conditions.

Future Outlook

The company expects the next say-on-pay vote will occur at the 2025 annual meeting of stockholders.

Management Comments

• We appreciate your continued support of our Company, stated by Order of the Board of Directors, MARLAN D. WALKER Chief Executive Officer.

Industry Context

This proxy statement is a standard document for publicly traded companies, outlining corporate governance matters and seeking stockholder votes on key issues.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The company's executive compensation practices are disclosed in accordance with SEC regulations, allowing for comparison to peer companies.
• The company's corporate governance policies, such as director independence and committee charters, align with Nasdaq listing requirements and best practices.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into subscription agreements with Rubric Capital Management LP, where Justin Roberts, a director, is a Partner.
• The company redeemed all outstanding shares of the Company's Series A Preferred Stock from Rubric at a purchase price of $1,333 per share.
• The Company also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between the Company and Rubric.
• On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797 pursuant to the subscription agreement and received gross proceeds of $1.15 million before expenses.
• On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761.
• We received gross proceeds of $2.0 million from the drawdown before expenses.

Stakeholder Impact

• Stockholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Executive officers' compensation is designed to align with stockholder value creation.
• The appointment of an independent auditor ensures the integrity of the company's financial statements.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on December 5, 2024.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, independent auditor, corporate governance, TherapeuticsMD